Trial 2N-21-6


A Phase 2 Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on or are Intolerant to a PD-1/L-1, EGFR, or ALK Inhibitor

Type: Treatment
Phase: Phase II
Status: Closed to Accrual with Ongoing Follow-up
Treatments: Immunotherapy, Other
Randomized: Yes
USC Satellite Location: USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Jorge Nieva, M.D.
Other Trial Staff:  Kristy Sartor Massopust, Coordinator, Sreebharathy Venkatesh, D.M., Anisa Sandin, Coordinator, Andrew Zeng, Coordinator, Sophia Marmolejo, Coordinator, Sandy Tran, Coordinator, Azucena Vera, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.